Publications by authors named "Marco Airoldi"
Article Synopsis
- This review examines the effectiveness of anti-EGFR therapy as a first-line treatment for patients with left-sided metastatic colorectal cancer (mCRC) that have RAS wild-type mutations.
- It emphasizes the variability in patients' responses to this therapy based on molecular differences and clinical factors, suggesting a need for a personalized treatment approach.
- The review critiques existing guidelines, citing recent evidence to highlight the importance of understanding biomarkers and tumor biology in selecting the best treatment options for individuals.
Thymic epithelial tumors (TETs) are rare mediastinal cancers originating from the thymus, classified in two main histotypes: thymoma and thymic carcinoma (TC). TETs affect a primary lymphoid organ playing a critical role in keeping T-cell homeostasis and ensuring an adequate immunological tolerance against "self". In particular, thymomas and not TC are frequently associated with autoimmune diseases (ADs), with Myasthenia Gravis being the most common AD present in 30% of patients with thymoma.
View Article and Find Full Text PDFArticle Synopsis
- Recent advances have led to new treatment options for metastatic colorectal cancer (mCRC), particularly for patients who have undergone extensive prior therapies.
- Fruquintinib, a tyrosine kinase inhibitor, has shown good effectiveness and safety in clinical trials (FRESCO and FRESCO 2) for heavily pretreated mCRC patients.
- The review suggests creating a treatment algorithm to incorporate fruquintinib as a standard alongside other effective therapies for different patient profiles.
Background And Aims: Lynch syndrome (LS) is currently one of the most prevalent hereditary cancer conditions, accounting for 3% of all colorectal cancers and for up to 15% of those with DNA mismatch repair (MMR) deficiency, and it was one of the first historically identified. The understanding of the molecular carcinogenesis of LS tumors has progressed significantly in recent years. We aim to review the most recent advances in LS research and explore genotype-based approaches in surveillance, personalized cancer prevention, and treatment strategies.
View Article and Find Full Text PDFThymic epithelial tumors (TETs) comprise a rare group of thoracic cancers, classified as thymomas and thymic carcinomas (TC). To date, chemotherapy is still the standard treatment for advanced disease. Unfortunately, few therapeutic options are available for relapsed/refractory tumors.
View Article and Find Full Text PDFThe therapeutic landscape in locally advanced rectal cancer (LARC) has undergone a significant paradigm shift in recent years with the rising adoption of total neoadjuvant treatment (TNT). This comprehensive approach entails administering chemotherapy and radiation therapy before surgery, followed by optional adjuvant chemotherapy. To establish and deliver the optimal tailored treatment regimen to the patient, it is crucial to foster collaboration among a multidisciplinary team comprising healthcare professionals from various specialties, including medical oncology, radiation oncology, surgical oncology, radiology, and pathology.
View Article and Find Full Text PDF